Lundbeck.com.tr internet sayfasından ayrılıyorsunuz.
Projeler | Hastalık | 1. Faz | 2. Faz | 3. Faz | Ruhsat Başvurusu | ||||
---|---|---|---|---|---|---|---|---|---|
Eptinezumab (anti-CGRP mAb) | Migraine prevention | Filing | |||||||
Hareket Modu Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
Eptinezumab (anti-CGRP mAb) | Episodic cluster headache | 3 | |||||||
Hareket Modu Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. |
|||||||||
Brexpiprazole* | Agitation in Alzheimer's disease (AADAD) | 3 | |||||||
Hareket Modu Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Brexpiprazole* | PTSD | 3 | |||||||
Hareket Modu Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD (post-traumatic stress disorder) symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Aripiprazole 2-month injectable* | Schizophrenia + Bipolar I disorder | 1 | |||||||
Hareket Modu Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed. *Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. |
|||||||||
Lu AG06466 (MAGL inhibitor) | PTSD, MS spasticity, etc. | 1 | |||||||
Hareket Modu Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and decrease neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including post-traumatic stress disorder (PTSD), focal epilepsy, and spasticity in patients with multiple sclerosis (MS). * PTSD, focal epilepsy, and MS spasticity Ph1b studies have been initiated. |
|||||||||
Lu AF82422 (anti-alpha-synuclein mAb) | Multiple system atrophy | 2 | |||||||
Hareket Modu Lu AF82422 is a monoclonal antibody (mAb) targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders. |
|||||||||
Lu AF28996 (D1-D2 agonist) | Parkinson's disease | 1 | |||||||
Hareket Modu Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients. |
|||||||||
Lu AG09222 (anti-PACAP mAb) | Migraine prevention | 2 | |||||||
Hareket Modu Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology. |